Recently, Xiangyu Medical issued an announcement responding to a proposed share reduction plan by certain shareholders. The company stated that it has received notifications from shareholders holding more than 5% of its shares, as well as some directors, supervisors, and senior management, indicating their intention to sell no more than 2% of the company’s total shares within the next six months via centralized bidding or block trading, citing personal liquidity needs. Xiangyu Medical emphasized that this planned reduction is solely for the shareholders’ personal financial arrangements and will not significantly impact the company’s governance structure, core operations, or ongoing business capabilities. The company affirmed that its current operations remain stable, its financial condition is sound, and all business activities are progressing normally. It also reminded investors to be mindful of secondary market risks and make rational investment decisions. As a leading domestic player in rehabilitation medical devices, Xiangyu Medical has consistently increased R&D investment, expanded its product portfolio, and actively advanced into the intelligent rehabilitation equipment market. Although short-term share price volatility may occur due to the announced reduction, the company’s fundamentals remain unchanged. Market analysts suggest investors focus on the company’s long-term strategy and industry outlook rather than short-term fluctuations.
近日，翔宇医疗发布公告，回应部分股东拟实施的减持计划。公司表示，已收到持股5%以上股东及部分董监高的通知，其因自身资金需求，计划在未来六个月内通过集中竞价或大宗交易方式减持不超过公司总股本2%的股份。翔宇医疗强调，此次减持系股东个人资金安排，不会对公司治理结构、主营业务及持续经营能力产生重大影响。公司目前经营状况稳定，财务状况良好，各项业务正常推进。同时，翔宇医疗提醒投资者注意二级市场交易风险，理性决策。作为国内康复医疗器械领域的领先企业，翔宇医疗近年来持续加大研发投入，拓展产品线，并积极布局智能化康复设备市场。尽管短期股价可能受减持消息扰动，但公司基本面未发生实质性变化。市场分析人士指出，投资者应关注公司长期发展战略及行业前景，而非短期波动。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/14259.html